SCHEMBL4465485

SCHEMBL4465485

O=C(Nc1ccccc1)NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.61
SMN1; SMN2 Q16637 6/20 0.61
MEN1 O00255 6/20 0.61
KMT2A Q03164 6/20 0.61
MAPT P10636 5/20 0.61
FBP1 P09467 1/20 0.57
ACP1 P24666 2/20 0.57
HTT P42858 4/20 0.50
RECQL P46063 3/20 0.50
CYP2C9 P11712 1/20 0.48
TP53 P04637 1/20 0.46
EPHX1 P07099 1/20 0.46
TSHR P16473 1/20 0.46
EPHX2 P34913 1/20 0.46
CDK9 P50750 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
P2RY12 Q9H244 1/20 0.46
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922237 0.91 MEN1 (0.59) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL9920076 0.90 MEN1 (0.57) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL9424721 0.88 MAPT (0.58) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL1547882 0.87 MAPT (0.54) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL9920082 0.86 KMT2A (0.60) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL1548436 0.82 SCN2A (0.50) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL1548077 0.81 MAPT (0.54) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL9923098 0.79 P2RY12 (0.45) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL9920074 0.79 POLB (0.45) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL9922955 0.79 FBP1 (0.47) LMNASMN1; SMN2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009067607-A2 COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS MEMORY PHARMACEUTICALS CORPORATION (US) 2009-05-28 WO disclosed